spironolactone/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases 24-hour ambulatory systolic blood pressure
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared with placebo and no treatment, spironolactone significantly reduced the 24-hour ambulatory SBP (WMD = −10.31, 95% CI = −12.86 to −7.76, P <.001) (WMD = −11.00, 95% CI = −19.25 to −2.75).”
Quoted verbatim from Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Patients with resistant hypertension, spironolactone added to background antihypertensive therapy versus placebo and versus no treatment, pooled from randomised trials
Effect -10.31 mean difference, 95% CI -12.86 to -7.76
Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.2020PMID:32846786Permalink
Keep reading
- Everything the graph holds on spironolactone
- Every compound studied against 24-hour ambulatory systolic blood pressure
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45C8RTRPDDVZYF09MREVCXP